ATR vs TGTX
AptarGroup vs TG Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TGTX
TG Therapeutics, Inc.
60
Watch
| Metric | ATR | TGTX |
|---|
| AI Score |
69
|
60
|
| Price |
$134.62
|
$49.86
|
| P/E Ratio |
24.06×
|
16.39×
|
| ROE |
14.7%
|
69.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.3%
|
82.4%
|
| Debt / Equity |
0.54×
|
1.25×
|
| Dividend Yield |
1.4%
|
0.0%
|
| RSI (14) |
48.2
|
42.0
|
| Beta |
0.382
|
1.666
|
| Expected Upside |
+1.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for ATR versus TGTX.
ATR leads by 9 points.
ATR scores 69/100 (Buy) versus TGTX at 60/100 (Watch).
ATR Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TGTX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 76.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 22.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 72.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- EPS growing 633.7% YoY — Growth
Bear Case
- Price-to-book of 21.1x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 22.5% signals elevated volatility — Risk